Tredje AP-fonden’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tredje AP-fonden’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.49M	Buy	+60,944	New	+$3.34M	0.02%	400
2026 Q1	–	Sell	-271,999	Closed	-$16.2M	–	557
2025 Q4	$16.2M	Sell	271,999 -24,940	-8%	-$1.36M	0.12%	127
2025 Q3	$16.1M	Buy	296,939 +6,197	+2%	+$354K	0.13%	124
2025 Q2	$16M	Buy	290,742 +4,078	+1%	+$240K	0.13%	111
2025 Q1	$20.3M	Buy	286,664 +63,000	+28%	+$4.24M	0.19%	105
2024 Q4	$14.7M	Buy	223,664 +194,334	+663%	+$13M	0.13%	128
2024 Q3	$2.06M	Hold	29,330	–	–	0.02%	362
2024 Q2	$2.41M	Sell	29,330 -463	-2%	-$38.5K	0.02%	320
2024 Q1	$2.6M	Hold	29,793	–	–	0.03%	320
2023 Q4	$2.87M	Sell	29,793 -1,185	-4%	-$105K	0.04%	298
2023 Q3	$2.74M	Sell	30,978 -2,883	-9%	-$257K	0.04%	293
2023 Q2	$2.94M	Sell	33,861 -5,547	-14%	-$522K	0.04%	301
2023 Q1	$3.83M	Buy	39,408 +1,914	+5%	+$198K	0.06%	233
2022 Q4	$3.88M	Sell	37,494 -239	-0.6%	-$22.4K	0.07%	214
2022 Q3	$3.2M	Buy	+37,733	New	+$3.36M	0.07%	221

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Tredje AP-fonden's BMRN Position: Q2 2026 in Review

Tredje AP-fonden opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 60,944 shares worth $3.49M. The stake represents 0.02% of the portfolio and ranks #400 among its holdings. This is a return to the name: Tredje AP-fonden previously reported a position in BMRN as recently as Q4 2025.

Tredje AP-fonden first reported a position in BMRN in Q3 2022 and has held it in 15 quarters since. The position peaked at $20.3M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Tredje AP-fonden held 60,944 shares of BioMarin Pharmaceuticals worth $3.49M as of Q2 2026.
BioMarin Pharmaceuticals was a new Tredje AP-fonden position in Q2 2026.
BioMarin Pharmaceuticals made up 0.02% of Tredje AP-fonden's portfolio in Q2 2026, its #400 holding.
Tredje AP-fonden first reported a position in BioMarin Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Tredje AP-fonden's BioMarin Pharmaceuticals position peaked at $20.3M in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Tredje AP-fonden's 13F filing for Q2 2026, filed 10 Aug 2026.